Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus
Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus
复制标题
DOI：
10.1016/j.metabol.2005.08.017
复制
发表时间：
2006-02-01
影响因子：
9.8
通讯作者：
Agardh, E
中科院分区：
文献类型：
--
作者：
Fosmark, DS;Torjesen, PA;Agardh, E
晚期糖化终产物（AGEs）被认为在糖尿病视网膜病变中起主要的致病作用。最重要的AGE是未知的，但由于2型糖尿病患者血清中甲基乙二醛衍生的氢咪唑酮增加，本研究的目的是阐明氢咪唑酮血清水平与2型糖尿病患者视网膜病变之间的可能关联。我们招募了227名患有2型糖尿病和视网膜病变的患者，从无视网膜病变到增生性视网膜病变。根据糖尿病视网膜病变早期治疗研究，通过每只眼睛7张标准视场立体照片确定视网膜病变水平。患者年龄66±11岁，已知糖尿病病程14.9年。采用竞争性免疫分析法测定血清氢咪唑酮水平。非增殖性视网膜病变（中位数为4.50 U/mL，四分位数范围为3.69 ~ 5.77 U/mL）和增殖性视网膜病变（中位数为4.88 U/mL，四分位数范围为3.70 ~ 6.52 U/mL）患者血清氢咪唑酮水平均高于非视网膜病变患者（中位数为4.02 U/mL，四分位数范围为3.47 ~ 4.88 U/mL） （P = 0.008和P = 0.008）。002年,分别)。氢咪唑酮与血红蛋白A（1c）无相关性（r = 0.04, P = 0.57）。此外，与非增殖性视网膜病变患者（中位数为4.34，四分位数范围为3.86-5.53U/mL, P = 0.015）相比，增殖性视网膜病变患者的血清氢咪唑酮水平（中位数为6.91 U/mL，四分位数范围为4.70-8.91 U/mL）较已知糖尿病病程较短的患者（中位数为6.91 U/mL，四分位数范围为4.70-8.91 U/mL）升高。伴有视网膜病变的2型糖尿病患者血清氢咪唑酮水平升高。这种关联是独立于迄今已知的相关因素，如血红蛋白A（1c）。(c) 2006爱思唯尔公司版权所有。
Advanced glyeation end products (AGEs) are thought to play a major pathogenic role in diabetic retinopathy. The most important AGE is unknown, but as increased serum methylglyoxal-derived hydroimidazolone has been demonstrated in patients with type 2 diabetes mellitus, the aim of the present study was to elucidate possible associations between serum levels of hydroimidazolone and retinopathy in patients with type 2 diabetes mellitus. We recruited 227 patients with type 2 diabetes mellitus and retinopathy ranging from none to proliferative. Level of retinopathy was determined from 7 standard field stereo photographs per eye according to the Early Treatment Diabetic Retinopathy Study. The patients were 66 +/- 11 years old, with a known diabetes duration of 14 9 years. Serum levels of hydroimidazolone were determined with a competitive immunoassay. Serum levels of hydroimidazolone were increased in nonproliferative (median, 4.50 U/mL; interquartile range, 3.69-5.77 U/mL) and proliferative retinopathy (median, 4.88 U/mL; interquartile range, 3.70-6.52 U/mL) compared with patients without retinopathy (median, 4.02 U/mL; interquartile range, 3.47-4.88 U/mL) (P =.008 and .002, respectively). There was no association between hydroimidazolone and hemoglobin A(1c) (r = 0.04, P =.57). In addition, patients with proliferative retinopathy and a relatively short known duration of diabetes, that is, less than the median of 14 years, had increased serum levels of hydroimidazolone (median, 6.91 U/mL; interquartile range, 4.70-8.91 U/mL) compared with those with nonproliferative retinopathy (median, 4.34; interquartile range, 3.86-5.53U/mL, P =.015). Serum levels of hydroimidazolone are increased in type 2 diabetic patients with retinopathy. This association is independent of hitherto known associated factors, such as hemoglobin A(1c). (c) 2006 Elsevier Inc. All rights reserved.